

THOMPSON STREET

CAPITAL PARTNERS

THOMPSON STREET CAPITAL PARTNERS COMBINES TWO BIOLOGICAL PRODUCT/RESEARCH COMPANIES UNDER THE BIORECLAMATIONIVT BRAND

ST. LOUIS (July 1, 2013) – Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that portfolio companies Bioreclamation and In Vitro Technologies will now operate as one company under the shared BioreclamationIVT name.

The consolidated company will offer expanded and more coordinated customer service capabilities with a wider geographical presence by combining the substantial resources of both organizations:

Bioreclamation, headquartered in Westbury, New York, has made its name as a worldwide provider of biological products to life sciences and pharmaceutical companies. The company was acquired by TSCP and management in April, 2013, to begin building a leading biological products platform.

In Vitro Technologies, headquartered in Baltimore, is a provider of hepatocyte cells and other in vitro research tools to support the screening of drug compounds in early-stage drug discovery and development. The company was acquired by TSCP and management in June of 2013.

Bob Dunn, Managing Director, TSCP, said, “The new BioreclamationIVT platform combines two excellent management teams, their collective arrays of products and services, highly specialized and sophisticated sourcing and quality control processes, and a unique capacity to offer an extensive range of biologics and differentiated in-vitro research tools to their customers.”

Added Mr. Dunn, “We are excited at the prospect of growing this platform even further, while maintaining our businesses’ industry-leading focus on product scope, quality and customer service.”

###